ArticleCanadian journal of kidney health and disease2026
A Canadian Survey of Prescribing Practices of Erythropoiesis-Stimulating Agents in Dialysis-Dependent and Non-Dialysis-Dependent Chronic Kidney Disease.
Article in Canadian journal of kidney health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Erythropoiesis-stimulating agents (ESAs) are commonly used to manage chronic kidney disease (CKD)-associated anemia. There is a paucity of clear guidelines on their use in patients with CKD and with history of stroke or malignancy. Objective: To identify hemoglobin targets/thresholds, ESA prescribing practices and patterns, and prescriber comfort in patients with CKD and with history of stroke or malignancy. Study Design and Setting: We administered an online, cross-sectional survey to nephrologists, nephrology trainees, nurse practitioners, and pharmacists affiliated with the Canadian Society of Nephrology (CSN) from March 11 to June 30, 2024. Methods: Survey questions were designed to determine the prescribing practices of ESAs for both general patients with CKD and those with CKD and history of stroke, active malignancy, or prior malignancy. Survey design was finalized using a 4-stage modified Delphi process. Ordinal regression was used to assess the association between baseline characteristics and prescriber comfort. Results: In all, 24% (127/540) of potential participants responded, with 121 responses included in the final survey analysis. Most respondents were nephrologists (67%, 81/121). Only 9%, 7%, and 4% of respondents reported having an institutional protocol for anemia management for patients with CKD and history of stroke, active malignancy, or previous malignancy, respectively. The most common hemoglobin target for general patients with CKD was 95 to 115 g/L. For those with history of stroke, active, or previous malignancy, it was 90 to 105 g/L. Self-reported prescriber comfort was greatest in general patients with CKD. Among all prescribers, comfort ratings were significantly lower when prescribing ESAs in those with stroke or malignancy. Nephrologists and nephrology trainees were more likely to report higher comfort ratings when prescribing ESAs in patients with CKD and active malignancy (odds ratio [OR] = 2.80, 95% confidence interval [CI] = 1.12-6.96) compared with nonphysicians. Limitations: There was a potential for nonresponse bias given the response rate of 24%. Sampling bias may have been introduced with convenience sampling of solely kidney care providers affiliated with the CSN. Conclusion: This study highlights the variability of ESA prescribing practices and anemia management across Canada in patients with CKD and with stroke or malignancy. Our findings emphasize the need for guidelines to manage ESA prescribing in these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.